Epitranscriptomics of cardiovascular diseases (Review)

Abstract

RNA modifications have recently become the focus of attention due to their extensive regulatory effects in a vast array of cellular networks and signaling pathways. Just as epigenetics is responsible for the imprinting of environmental conditions on a genetic level, epitranscriptomics follows the same principle at the RNA level, but in a more dynamic and sensitive manner. Nevertheless, its impact in the field of cardiovascular disease (CVD) remains largely unexplored. CVD and its associated pathologies remain the leading cause of death in Western populations due to the limited regenerative capacity of the heart. As such, maintenance of cardiac homeostasis is paramount for its physiological function and its capacity to respond to environmental stimuli. In this context, epitranscriptomic modifications offer a novel and promising therapeutic avenue, based on the fine-tuning of regulatory cascades, necessary for cardiac function. This review aimed to provide an overview of the most recent findings of key epitranscriptomic modifications in both coding and non-coding RNAs. Additionally, the methods used for their detection and important associations with genetic variations in the context of CVD were summarized. Current knowledge on cardiac epitranscriptomics, albeit limited still, indicates that the impact of epitranscriptomic editing in the heart, in both physiological and pathological conditions, holds untapped potential for the development of novel targeted therapeutic approaches in a dynamic manner.

Exercise Mitigates Endothelial Pyroptosis and Atherosclerosis by Downregulating NEAT1 Through N6-Methyladenosine Modifications

“…8,36 Under physiological and pathological conditions, episodic transcriptome alterations of noncoding RNAs are highly prevalent. 37 There are 2 types of noncoding RNAs: miRNAs (<50 nucleotides in length) and lncRNAs (>200 nucleotides in length). lncRNAs regulate gene expression in a more complicated manner and are more stable in cells than other RNAs.…”

Phospholamban R14del disease: The past, the present and the future

“…Since its discovery in 2006, the PLN-R14del mutation has been attracting an ever increasing research interest worldwide and PLN shown to contribute at varying degrees to disease pathology, while a number of other levels of molecular complexity, such as micro-RNAs, epigenetics and epitranscriptomics, remain to be explored (96)(97)(98)(99). While some of the experimental findings may appear conflicting at times, the intense, complementary efforts of the international PLN scientific community ensure continued progress with encouraging prospects towards the identification of promising therapeutic targets.…”

Epigenetics of Early Cardiometabolic Disease: Mechanisms and Precision Medicine

“…In the human heart, m6A patterns have been associated with cardiovascular remodeling, cardiac hypertrophy, ischemic heart disease, and heart failure. 72,73 Some recent data show that CVD risk factors can modify m6A, including in easy-to-collect biospecimens such as blood RNA. For instance, Kupsco et al showed in a study in Beijing, China, that the total levels of blood m 6 A were decreased in long-term smokers compared with nonsmokers.…”